Tracing the Treatment Journey Using Real-World Data
Like the pharmaceutical industry as a whole, the market research and business intelligence functions within have experienced a tremendous... In DRG Blog/ September, 2019 RNA-Based Therapies: 5 Key Takeaways for Biopharma Strategists
The following is an excerpt from the eBook RNA-based Therapies: Takeaways and Best Practices for Strategy Planning Although no RNA therapies are... In DRG Blog, Drug Watch/ February, 2019 The Fall and Rise of Evenity – Amgen/UCB/Astellas’s Osteoporosis Hope
A history of Evenity's development, and the wider implications of the FDA advisory committee's decision to recommend the approval of Evenity. The... In DRG Blog, Drug Watch/ February, 2019 Checkpoint Inhibitors: 9 Key Takeaways for Biopharma Strategists
The following is an excerpt from the eBook Checkpoint Inhibitors: Takeaways and Best Practices for Strategic Planning It’s very clear that the... In DRG Blog, Drug Watch/ January, 2019 The Future of Rheumatology
Topics of discussion at the annual ACR/ARHP in October 2018 The annual meeting of the American College of Rheumatology/American Rheumatology Health... In DRG Blog, Drug Watch/ December, 2018 The Microbiome: The New Frontier for the Treatment of Major Depressive
Introduction: Major depressive disorder (MDD) is a highly prevalent condition, affecting approximately 42 million people in the G7 (France, Germany... In DRG Blog, Drug Watch/ November, 2018 PARP Inhibitors Updates from ESMO 2018
PARP inhibitors have generated huge excitement with their recent approvals in ovarian and breast cancer, these agents are making a meaningful... In DRG Blog, Drug Watch/ October, 2018 Opportunities for Drug Development in Gastroesophageal Cancer
Does the future market value for gastroesophageal cancer reflect the effectiveness of emerging treatments? Key findings: In a new report from... In DRG Blog, Drug Watch/ October, 2018 Microbiome-Based Therapies are Poised to Launch Within the Next Decade
How will emerging microbiome-based therapies impact disease markets, especially in gastrointestinal diseases? Key Findings: Research on the human... In DRG Blog, Drug Watch/ October, 2018 Addressing High Cost of Drugs in HIV
Will New Generics make the Cost of care Affordable? The cost of care for HIV patients continues to increase year over year, which combined with a... In DRG Blog, Drug Watch/ October, 2018 The Drugs don’t Work. Or do They?
The PROs and CONS of Prescription Weight Loss Medications World Obesity Day is on October 11, and it is a timely reminder of the obesity epidemic... In DRG Blog, Drug Watch/ October, 2018 Microbiome-Based Therapies 101
The human microbiome is composed of diverse populations that include bacteria, fungi, bacteriophages and viruses, and it is unique to each... In DRG Blog, Drug Watch/ October, 2018 Forecasting the Market Impact of Generic Xeljanz
What are the most important factors to consider when forecasting the launch of generic Xeljanz? Pfizer’s Xeljanz was the first Janus kinase (Jak... In DRG Blog, Drug Watch/ September, 2018 Emerging SMA therapies are poised to address longstanding unmet needs
How will emerging SMA therapies address longstanding unmet needs, and where will remaining market opportunies lie? Key findings: Biogen/Ionis’s... In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018 Anti-NGFs for Chronic and Osteoarthritic Pain
How Safe will be Safe Enough for Regulators and Payers? In August 2018, FDA Commissioner Scott Gottlieb provided an update to the ongoing efforts... In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018 The Current Regulatory Environment for Microbiome-Based Therapies: Insights from the FDA's Workshop on Live Bacterial Products
Microbiome-based therapies, which aim to modify the bacterial ecosystem that colonizes the human body, have been a hot area of research for the... In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018 September is Interstitial Cystitis Awareness Month: A Therapy Area With High Unmet Clinical Need
Interstitial cystitis, a urological disorder that is more formally known as interstitial cystitis/bladder pain syndrome (ICBPS), is characterized... In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018 Heart of Gold: Belviq and the Emerging Cardiovascular Outcomes Data for Obesity Pharmacotherapies
“Showing additional CV benefits is important for obesity therapies. It will hopefully remove some of the stigma against these drugs as being... In DRG Blog, Drug Watch, Niche and Rare Disease/ September, 2018 ESC 2018 Highlights: Sink or Sail for Xarelto?
Continuing in tradition, this year’s European Society of Cardiology (ESC) Congress, which was held during August 25-29 in Munich, again witnessed... In DRG Blog, Drug Watch, Niche and Rare Disease/ August, 2018 What is in Store for the Hyperkalemia Market?
Hyperkalemia describes abnormally elevated levels of serum potassium, a complication that occurs frequently among patients with renal insufficiency... In DRG Blog, Drug Watch, Niche and Rare Disease/ August, 2018